Gensight Biologics (XPAR:SIGHT) ROCE % : 0.00% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Gensight Biologics's annualized ROCE % for the quarter that ended in Dec. 2023 was 0.00%.

Gensight Biologics ROCE % Historical Data

The historical data trend for Gensight Biologics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gensight Biologics ROCE % Chart

Gensight Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-127.52

-127.58

-81.83

-109.26

Gensight Biologics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-91.30	-70.87	-189.40	-	-

Gensight Biologics ROCE % Calculation

Gensight Biologics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-23.069	/	( ( (25.941 - 14.642)	+	(9.132 - 25.29) )	/ 2 )
	=	-23.069	/	( (11.299	+	-16.158)	/ 2 )
	=	-23.069	/	-2.4295
	=	949.54 %

Gensight Biologics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-24.902	/	( ( (16.732 - 30.584)	+	(9.132 - 25.29) )	/ 2 )
	=	-24.902	/	( ( -13.852	+	-16.158 )	/ 2 )
	=	-24.902	/	-15.005
	=	0 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Gensight Biologics (XPAR:SIGHT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Gensight Biologics ROCE % Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gensight Biologics (XPAR:SIGHT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

GSGTF:USA G49N:Germany

Address

74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012

Website

https://www.gensight-biologics.com

Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines